MDXH Company Profile and Key Details

MDXH has shown mixed momentum, gaining 4.37% over the past week and -10.72% over the past quarter, though year-to-date performance is up 0.28%. Short-term trend indicators are bearishly aligned (SMA20 0.01%, SMA50 1.01%, SMA200 8.27%). The stock’s 14-day RSI is 49.14 (neutral), while the ATR of 0.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -33.4% below its high and over 162.96% above its low. Average 10-day trading volume of 416.87 thousand shares is below the 3-month average of 835.49 thousand, indicating normal recent market interest.

MDxHealth S.A. has 49.50 million shares outstanding. The public float is 35.02 million shares, elevated short interest at 0.29% of float. This equals 118.95 thousand shares. The short ratio is 2.07 days. Institutional investors hold 43.02% of the float. Insiders own 11.13%.

The stock is currently mid-range between its 52-week high and low $0.40 and $5.33. With a market capitalization of about $21.81 million, MDxHealth S.A. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.38). Key stats such as the average daily volume over the past year has been around 839.44 thousand shares, volume is running light vs its 52-week average. Headquartered in Herstal, WA, MDxHealth S.A. operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Michael K. McGarrity, the company employs approximately 364 people and listed since November 04, 2021. MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe.

MDxHealth S.A. generated EPS of -$0.64 over the past year. Five-year average earnings growth is 29.99%. The latest quarter delivered EPS of -$0.17. The next quarter is forecast at -$0.13. Next year's EPS is expected at $30.90. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $1.50. The high target offers 2042.86% upside. The low target suggests 257.14% downside. The mean target is $5.79. This offers 1278.57% upside. MDxHealth S.A. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 13, 2026, missed forecasts by 30.77%. The prior quarter beat by 30.77%. Over the last six quarters, Apple has recorded several small beats. These include -33.33% in February 26, 2025.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

MDxHealth S.A. trades at a P/E ratio of -0.63, slightly below the S&P 500 average, with a price-to-sales ratio of 0.27 and a price-to-book ratio of -1.75 indicating negative book value, which may reflect financial stress. The P/FCF stands at -13.26, also below market averages.

MDxHealth S.A. (NASDAQ:MDXH) shares are flat 0.28% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows MDxHealth S.A. trading at a premium to the broader market with a P/E of -0.63. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.12, suggesting 1819.62% upside. Our AI forecast model points to short-term weakness (-12.53% over two weeks), a medium-term fall (-74.0% over three months), and a longer-term loss (-97.64% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that MDxHealth S.A. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -12.53%, with price expected at $0.37 by August 04, 2026, within a range of $0.33 to $0.42 3-Month Outlook: Projected fall of -74.0%, reaching $0.11 by October 19, 2026, with a range of $0.03 to $0.18. 1-Year Outlook: Projected loss of -97.64%, with price at $0.01 by July 21, 2027, within a range of $0.00 to $0.00.